Corporate Actions
Material events companies report to the SEC on Form 8-K: mergers, dividends, buybacks, splits, management changes, bankruptcies and more. Enter a ticker for one company's history, or browse the latest across the market.
Gossamer Bio (GOSS)
1 8-K filing| Filed | Action | What the filing says | SEC |
|---|---|---|---|
| Feb 23, 2026 |
Other Events
Item 8.01Item 9.01
|
Other Events. On February 23, 2026, Gossamer Bio, Inc. (the “Company” or “Gossamer”) announced topline results from its Phase 3 PROSERA study of seralutinib in patients with pulmonary arterial hypertension (PAH)…Other Events. On February 23, 2026, Gossamer Bio, Inc. (the “Company” or “Gossamer”) announced topline results from its Phase 3 PROSERA study of seralutinib in patients with pulmonary arterial hypertension (PAH). Seralutinib is an investigational, inhaled tyrosine kinase inhibitor targeting PDGFR, CSF1R, and c-KIT, delivered via dry powder inhalation for the treatment of pulmonary arterial hypertension. The Phase 3 PROSERA Study enrolled 390 patients with WHO Functional Class (FC) II or III PAH, with 197 randomized to the seralutinib arm and 193 randomized to the placebo arm. 55% of the enrolled patients were on background triple or quadruple PAH therapy, and 61% were on background prostacyclin therapy. The treatment and placebo arms were generally well balanced. At Week 24, patients receiving seralutinib had a median change of +28.2 meters in 6MWD from baseline, while patients receivin |
Filing 8-K |
Each 8-K is classified by its most significant item; hover an item number for its title. Classification and excerpts are read automatically and can be wrong; the filing on SEC.gov is the authority. For research, not investment advice.